Serum Phosphate and Mortality in Patients with Chronic Kidney Disease

Por Eddington, Helen, Hoefield, Richard, Sinha, Smeeta, Chrysochou, Constantina, Lane, Beverley, Foley, Robert N., Hegarty, Janet, New, John, O'Donoghue, Donal J., Middleton, Rachel J., Kalra, Philip A.
Publicado em 2010

Synthesis and biological evaluation of 2-styrylquinolines as antitumour agents and EGFR kinase inhibitors: molecular docking study

Por Magda A.-A. El-Sayed, Walaa M. El-Husseiny, Naglaa I. Abdel-Aziz, Adel S. El-Azab, Hatem A. Abuelizz, Alaa A.-M. Abdel-Aziz
Publicado em 2018-01-01

Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression

Por van der Wekken, A. J., Kuiper, J. L., Saber, A., Terpstra, M. M., Wei, J., Hiltermann, T. J. N., Thunnissen, E., Heideman, D. A. M., Timens, W., Schuuring, E., Kok, K., Smit, E. F., van den Berg, A., Groen, H. J. M.
Publicado no PLoS One (2017)

Arsenic Activates EGFR Pathway Signaling in the Lung

Por Andrew, Angeline S., Mason, Rebecca A., Memoli, Vincent, Duell, Eric J.
Publicado em 2009

Display of GPI-anchored anti-EGFR nanobodies on extracellular vesicles promotes tumour cell targeting

Por Kooijmans, Sander A. A., Aleza, Clara Gómez, Roffler, Steve R., van Solinge, Wouter W., Vader, Pieter, Schiffelers, Raymond M.
Publicado no J Extracell Vesicles (2016)

Synthesis, antitumour and antioxidant activities of novel α,β-unsaturated ketones and related heterocyclic analogues: EGFR inhibition and molecular modelling study

Por El-Husseiny, Walaa M., El-Sayed, Magda A.-A., Abdel-Aziz, Naglaa I., El-Azab, Adel S., Ahmed, Esam R., Abdel-Aziz, Alaa A.-M.
Publicado no J Enzyme Inhib Med Chem (2018)

Relationship between eGFR Decline and Hard Outcomes after Kidney Transplants

Por Clayton, Philip A., Lim, Wai H., Wong, Germaine, Chadban, Steven J.
Publicado no J Am Soc Nephrol (2016)

Design, Synthesis, Cytotoxic Evaluation and Molecular Docking of New Fluoroquinazolinones as Potent...

Por Zayed, Mohamed F., Ahmed, Sahar, Ihmaid, Saleh, Ahmed, Hany E. A., Rateb, Heba S., Ibrahim, Sabrin R. M.
Publicado no Int J Mol Sci (2018)

EGFR pathway polymorphisms and bladder cancer susceptibility and prognosis

Por Mason, Rebecca A., Morlock, Elaine V., Karagas, Margaret R., Kelsey, Karl T., Marsit, Carmen J., Schned, Alan R., Andrew, Angeline S.
Publicado em 2009

Quinazolinone-Amino Acid Hybrids as Dual Inhibitors of EGFR Kinase and Tubulin Polymerization

Por Zayed, Mohamed F., Rateb, Heba S., Ahmed, Sahar, Khaled, Osama A., Ibrahim, Sabrin R. M.
Publicado no Molecules (2018)

PROFILE 1014: lessons for the new era of lung cancer clinical research

Por Noonan, Sinead A., Camidge, D. Ross
Publicado no Transl Lung Cancer Res (2015)

Metabolic Syndrome and Triple-Negative Breast Cancer: A New Paradigm

Por Davis, Andrew A., Kaklamani, Virginia G.
Publicado em 2012

What's New in SCLC? A Review

Por Oronsky, Bryan, Reid, Tony R., Oronsky, Arnold, Carter, Corey A.
Publicado no Neoplasia (2017)

Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions

Por Oxnard, Geoffrey R., Lo, Peter, Nishino, Mizuki, Dahlberg, Suzanne, Lindeman, Neal I., Butaney, Mohit, Jackman, David M., Johnson, Bruce E., Jänne, Pasi A.
Publicado em 2013

A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature

Por Tsai, Alexander K., Oh, Seunguk, Chen, Hua, Shu, Yanqun, Ohlfest, John R., Vallera, Daniel A.
Publicado em 2010

Plasma oxalate in relation to eGFR in patients with primary hyperoxaluria, enteric hyperoxaluria and urinary stone disease

Por Perinpam, Majuran, Enders, Felicity T., Mara, Kristin C., Vaughan, Lisa. E., Mehta, Ramila A., Voskoboev, Nickolay, Milliner, Dawn S., Lieske, John C.
Publicado no Clin Biochem (2017)

New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?

Por Van Der Steen N, Caparello C, Rolfo C, Pauwels P, Peters GJ, Giovannetti E
Publicado em 2016-10-01

Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment

Por Morelli, M. P., Overman, M. J., Dasari, A., Kazmi, S. M. A., Mazard, T., Vilar, E., Morris, V. K., Lee, M. S., Herron, D., Eng, C., Morris, J., Kee, B. K., Janku, F., Deaton, F. L., Garrett, C., Maru, D., Diehl, F., Angenendt, P., Kopetz, S.
Publicado no Ann Oncol (2015)

Delay of treatment change following objective progression on first-line erlotinib in EGFR-mutant lung cancer

Por Lo, Peter C., Dahlberg, Suzanne E., Nishino, Mizuki, Johnson, Bruce E., Sequist, Lecia V., Jackman, David M., Jänne, Pasi A, Oxnard, Geoffrey R.
Publicado no Cancer (2015)

Interferon Tau Regulates PGF2α Release from the Ovine Endometrial Epithelial Cells via Activation of Novel JAK/EGFR/ERK/EGR-1 Pathways

Por Banu, Sakhila K., Lee, JeHoon, Stephen, Sam D., Nithy, Thamizh K., Arosh, Joe A.
Publicado no Mol Endocrinol (2010)